Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;35:621-625

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedrinelli, R.
Right arrow Articles by Mariani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedrinelli, R.
Right arrow Articles by Mariani, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMLODIPINE BESYLATE
*ENALAPRIL MALEATE
Medline Plus Health Information
*Edema
*High Blood Pressure
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Other hypertension

(Hypertension. 2000;35:621.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Amlodipine, Enalapril, and Dependent Leg Edema in Essential Hypertension

Roberto Pedrinelli; Giulia Dell’Omo; Elio Melillo; Mario Mariani

From Dipartimento Cardiotoracico (R.P., G.D., M.M.), Laboratorio Microcircolatorio (E.M.), Medicina Interna, Azienda Ospedaliera, Universita’ di Pisa, Italy.

Correspondence to Dr Roberto Pedrinelli, Dipartimento Cardiotoracico, Università di Pisa, 56100 Pisa, Italy. E-mail r.pedrinelli{at}int.med.unipi.it


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Calcium channel blockers (CCBs) blunt postural skin vasoconstriction, an autoregulatory mechanism that minimizes gravitational increases in capillary pressure and avoids fluid extravasation when standing. To evaluate the dose-response relation between this pharmacological interference and dependent edema, a frequent side effect of CCBs during antihypertensive treatment, skin blood flow (laser Doppler flowmetry) at the dorsum of the foot, both supine and with the limb passively placed 50 cm below the heart level, and leg weight (Archimedes principle) were measured at baseline, during increasing doses of the dihydropyridine amlodipine (5 and 10 mg UID each for 2 weeks), and after drug withdrawal in 10 hypertensive men. Because angiotensin-converting enzyme inhibitors may attenuate ankle swelling by CCBs, those parameters were evaluated according to a similar design during amlodipine (10 mg UID) and enalapril (20 mg UID) combined (n=10). As a control, the effect of enalapril monotherapy (10 and 20 mg UID for 2 weeks each) was evaluated in a third series of patients (n=8). Amlodipine (5 mg UID) increased leg weight without modifying postural vasoconstriction (the percent skin blood flow decrease from horizontal to dependent position), which indicates that extravascular fluid shift was independent of postural skin vasoconstriction. At 10 mg UID, however, amlodipine blunted postural vasoconstriction and increased leg weight further, which suggests that skin blood flow autoregulation limited additional fluid transfer. Both parameters normalized after drug withdrawal. Enalapril per se did not affect cutaneous vasomotion or leg weight but reduced the amount of dependent fluid extravasation by the CCB despite a persistent antagonism for postural vasoconstrictor responses.


Key Words: calcium antagonists • angiotensin-converting enzyme inhibitors • blood flow • vasoconstriction • hypertension, essential


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Precapillary resistance in the skin of the foot rises on standing, thereby limiting the increase in capillary pressure resulting from gravitational increases in transmural pressure.1 2 This autoregulatory vasoconstrictor mechanism is triggered by limb venous congestion and operates both through a locally evoked sympathetic axoaxonic reflex1 2 and local myogenic factors,3 with some minor participation of central mechanisms.2 The postural vasoconstrictor response protects subcutaneous tissue from fluid extravasation during dependency and eventually dependent edema1 ; its derangement, as in patients with peripheral vascular disease4 and diabetes,5 sets the stage for subcutaneous edema formation.6 We have recently shown impaired postural skin blood flow control in patients with essential hypertension who were treated with calcium channel blockers (CCBs).7 This pharmacological effect may contribute to ankle and/or pretibial edema in the absence of fluid retention,8 a frequent, bothersome, and still not completely understood collateral effect of calcium antagonist drugs.9

To test this hypothesis, we evaluated the relation between changes in postural skin vasomotion and objective measures of ankle swelling during treatment with graded doses of amlodipine, a dihydropyridine CCB.10 On the basis of previous reports of reduced ankle swelling during association therapy with angiotensin-converting enzyme inhibitors (ACEIs),11 12 we evaluated those parameters also during amlodipine treatment combined with enalapril, an ACEI.13 Skin blood flow was measured with the use of laser Doppler flowmetry (LDF), a noninvasive method that registers the sudden changes evoked by posture1 5 14 without entailing local heating of skin, injection, trauma, or venous occlusion, all of which may disturb local vasomotor reflexes. Fluid extravasation was indirectly assessed by measuring changes in leg weight by use of the Archimedes principle to measure water displacement induced by immersion of the leg.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Patients
The study was performed in 28 patients (age range 33 to 70 years) with uncomplicated stage I to II mild essential hypertension diagnosed by exclusion of secondary causes through history, physical examination, routine blood chemistry, and laboratory examinations. Only men were studied to avoid possible influences of menstrual cycles on systemic fluid status. All subjects had ankle/brachial systolic blood pressure (SBP) ratios of >1.0; none complained or showed evidence of venous disease. Patients were either never treated or had not received treatment for 1 month at the moment of the first baseline determination.

Experimental Protocol
The studies were performed between 2 and 4 PM and >=2 hours after the last food, drink, or smoking. Drugs were taken at approximately 8 AM, and measurements were obtained 6 to 8 hours from the last dosing. Patients were at ease with the medical staff and lay supine for >=30 minutes in a quiet, climatized room (22° to 24°C) at constant barometric pressure (range 756 to 768 mm Hg) and humidity (range 35% to 41%).

The general structure of the study consisted of measurement of LDF, leg weight, and blood pressure (BP) (1) at baseline, (2) after 4-week active treatment (see below), and (3) after 2-week drug withdrawal to evaluate recovery. Three active treatment protocols were performed.

Series 1 (n=10, age 54±6 years)
To characterize the dose-response profile of microvascular and fluid parameters to amlodipine, the drug was started at 5 mg UID for 2 weeks, increasing the dosage to 10 mg UID during the final 2 weeks.

Series 2 (n=10, age 58±9 years)
The interaction between calcium channel blockade and angiotensin-converting enzyme inhibition was assessed by adding amlodipine (10 mg UIDx2 weeks) in patients who received enalapril (20 mg UID) for the preceding 2 weeks.

Series 3 (n=8, age 58±7 years)
To evaluate the pattern of response to enalapril at different doses, a third group of patients was given 10 mg UID enalapril during the first 2 weeks and 20 mg UID enalapril during the final 2 weeks.

Experimental Methods
Laser Doppler Flowmetry
Skin blood flow was recorded with the use of a laser Doppler flowmeter (Periflux 4001 Master, Perimed Ltd). The device contains a solid-state, low-power diode laser (1 mW at the probe tip, wavelength 780 nm) that delivers a laser light to a cutaneous surface of {approx}1 mm2 at a depth of {approx}1 mm through flexible, graded-index, fiberoptic light guides. The laser light strikes moving red blood cells and is reflected with a shift in frequency, whereas nonmoving structures cause no shift in frequency.14 The reflected light is guided from the tissue surface through a second fiberoptic light guide, mixed, and analyzed in real-time by an analogue processor that provides a continuous output of the instantaneous mean Doppler frequency in the photocurrent identified by a square-law detector; the digitized signal was fed into a computer for on-line and off-line analyses. Before each study, the instrument was made null for a condition of no flow by placing the laser probe in the calibration clip on a surface containing no mobile structures and calibrated into a colloidal suspension of latex particles moving by brownian motion. Biological zero (ie, the laser Doppler flux recorded under no-flow conditions) was not subtracted because the precise nature of this measurement is still undetermined.15 16 Time-constant and sampling frequency were set at 0.03 seconds and 16 Hz, respectively. Double-sided adhesive disks were attached to the probes, which then were applied to the skin of the dorsal surface (first intermetatarsal space) of the right foot and left foot, an anatomic region characterized by predominance of precapillary arterioles17 under control of the intrinsic myogenic tone.3 18 Therefore LDF at this site reflects mainly nutritional capillary blood flow,18 which is to a large extent independent of sympathetic stimuli.7 18

Results (expressed in perfusion units, PU, were 1 PU equals 10 mV measured on the analogue output) were computer-derived, smoothed averages (Perisoft, Perimed Ltd) of skin blood flow recordings during the 2 minutes preceding foot lowering (leg dangling 50 cm below the heart level) and at the 9th and 10th minutes of foot dependency, when the parameter was invariably constant in all patients. Data measured at the heart (H) level and during dependency (D) were used to calculate percent postural changes [(H-D)/Hx100] as a measure of postural vasoconstriction. Intraindividual variability of the method as performed in our laboratory has been reported.7

Leg Weight
Leg weight was measured immediately after the LDF session with patients sitting comfortably on a chair. The right and left limbs were consecutively immersed up to the inner tibial tuberosity in a Plexiglas cube that contained lukewarm water (36° to 37°C) to avoid sudden vasoconstrictor responses. The entire water volume displaced by the maneuver dripped into a container set on a kitchen scale, thus allowing accurate (within 5 g) and reproducible (average variation coefficient 0.8%, n=5 determinations in 5 normal subjects) measurements.

Blood Pressure
SBP, diastolic BP (DBP), and mean BP (MBP, diastolic+1/3 pulse pressure) were measured with the use of an automated oscillometric device (NIBP KO 7267.004, Kontron Instruments) throughout the study sessions.

Statistics
LDF and limb weight at the right and left sides were averaged. BP values were the average of >=10 determinations. Descriptive statistics were medians and interquartile range for skewed data and mean±SD values otherwise. Statistical analysis was based on Wilcoxon’s signed-rank test for paired comparisons or Mann-Whitney test for 2-sample comparisons. A value of P<0.05 was the limit for statistical significance.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Baseline parameters were comparable in the patients allocated to the 3 different series (Tables 1, 2, and 3).


View this table:
[in this window]
[in a new window]
 
Table 1. Laser Doppler Flowmetry at the Dorsum of the Foot (Heart Level and During Dependency), Leg Weight, and Blood Pressure During Amlodipine


View this table:
[in this window]
[in a new window]
 
Table 2. Laser Doppler Flowmetry at the Dorsum of the Foot (Heart Level and During Dependency), Leg Weight, and Blood Pressure During Enalapril


View this table:
[in this window]
[in a new window]
 
Table 3. Laser Doppler Flowmetry at the Dorsum of the Foot (Heart Level and During Dependency), Leg Weight, and Blood Pressure During Enalapril and Amlodipine in Enalapril-Pretreated Patients

Laser Doppler Flowmetry
Resting and dependent skin flow increased dose dependently during amlodipine and recovered after drug withdrawal (Table 1). Postural vasoconstriction was blunted (P=0.006 versus baseline) only at the 10-mg UID dose because of a lesser decrease in dependent flow (Table 1 and Figure 1, left).



View larger version (11K):
[in this window]
[in a new window]
 
Figure 1. Box-and-whisker plots of postural changes in skin blood flow [(heart-dependent)/heartx100] at the dorsum of the foot (left; for the sake of clarity, negative signs are shown to indicate a reduction in flow) and changes in leg weight from baseline (right) during 5 and 10 mg UID amlodipine (AMLO) and recovery from drug effect. The central box encloses the middle 50% of the data; the vertical line inside the box represents the median, and the mean is plotted as a cross. Horizontal lines (whiskers) extend from each end of the box and cover 4 interquartile ranges. For statistics, see text and Table 1.

Microvascular parameters did not change during enalapril (Tables 2 and 3). Postural vasoconstriction was significantly blunted (P=0.03 versus baseline) by 10 mg UID amlodipine, even in enalapril-pretreated patients (Table 3 and Figure 2, left). The amount of inhibition induced by the CCB given alone or in combination did not differ (compare Figure 1 with Figure 2, left).



View larger version (11K):
[in this window]
[in a new window]
 
Figure 2. Box-and-whisker plot of postural changes in skin blood flow [(heart-dependent)/heartx100] at the dorsum of the foot (left; for the sake of clarity, negative signs are shown to indicate a reduction in flow) and changes in leg weight from baseline (right) during 20 mg UID enalapril (EN), 10 mg UID amlodipine, 20 mg UID enalapril combined (AMLO+EN), and recovery from drug effect. The central box encloses the middle 50% of the data; the vertical line inside the box represents the median, and the mean is plotted as a cross. Horizontal lines (whiskers) extend from each end of the box and cover 4 interquartile ranges. For statistics, see text and Table 3.

Leg Weight
No patient developed clinical evidence of ankle and/or pretibial pitting edema. Amlodipine increased leg weight by a median of 80 (68) g (P=0.006 versus baseline) at 5 mg and by an additional 68 g (65, P=0.059 versus 5 mg) at 10 mg, a cumulative increment of 136 g (range 40 to 230, P=0.006 versus baseline). Weight returned toward normal after drug withdrawal (Table 1 and Figure 1, right).

Leg weight did not change during enalapril (Tables 2 and 3) and increased when 10 mg UID amlodipine was added in enalapril-pretreated patients (Table 3 and Figure 2, right).

Weight gains during amlodipine (10 mg UID) with enalapril (20 mg UID) treatment were comparable to those observed during amlodipine monotherapy at one half that dosage [60 (90) versus 80 (68) g, respectively].

Blood Pressure
Amlodipine and enalapril decreased SBP, DBP, or both (Tables 1 and 2) without a dose-dependent relation. When the 2 drugs were combined (Table 3), BP dropped additively (mean percent MBP decrement: 10 mg UID amlodipine and 20 mg UID enalapril combined, 18%; 10 mg UID amlodipine, 13%; and 20 mg UID enalapril, 7%).

Correlations
The correlation between the intraindividual increments in leg weight and the decrements in postural vasoconstriction was not statistically significant, either in the overall group (r=-0.31, P=0.17, n=20) or in the subgroups of patients treated with amlodipine per se (r=-0.30, P=0.36, n=10) or combined with enalapril (r=-0.12, P=0.7, n=10) (Figure 3).



View larger version (17K):
[in this window]
[in a new window]
 
Figure 3. Relation between individual limb weight gains and attenuated postural vasoconstrictor responses during 10 mg UID amlodipine, either as monotherapy (•) or in combination with enalapril (x).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The aim of this clinical study was to evaluate the relation between skin blood flow autoregulatory vasoconstriction and dependent fluid extravasation during calcium channel blockade. The importance of this research stems from the present knowledge on the physiological role played by the local vasoconstrictor skin reflexes in humans.1 2 In fact, precapillary vasoconstriction caused by local myogenic factors and a locally evoked sympathetic axoaxonic reflex1 2 3 modulates gravitational increments in capillary pressure and brakes fluid filtration by raising plasma oncotic pressure as a consequence of slowed microvascular blood flow.19 20 21 22 Our data confirm previous results from our laboratory7 and other23 laboratories that show an antagonism of postural cutaneous vasoconstriction by CCBs, apparently not a specific property of dihydropyridines because verapamil, a chemically unrelated drug, behaved similarly.7 Influences from nonspecific vasorelaxation or functional antagonism against physiological vasoconstrictor mechanisms also could be excluded because {alpha}1-adrenoceptor blockers and angiotensin AT-1 receptor blockers such as doxazosin and losartan, respectively, were ineffective on cutaneous microcirculation.7 It is more probable that blunted postural vasoconstriction by CCBs reflected modulation of calcium fluxes24 maintaining myogenic tone, an extracellular calcium-dependent process25 involved in skin blood flow autoregulation.3 Our findings also show dose-dependent limb weight gains during administration of amlodipine, an interesting finding that indicates that dependent edema should not be seen as an occasional adverse event of CCBs, either dihydropyridine9 or no dihydropyridine (eg, see References 26 and 2726 27 ), but rather the extreme phenotype of a highly consistent pharmacological effect. In the context of our specific aims, though, the main outcome of the study was to show coexistence of dependent fluid extravasation with preserved postural control of skin blood flow by 5 mg UID amlodipine. Therefore net extravascular fluid shifts may occur independent from any interference with postural reflex skin vasoconstriction, in line with the knowledge about the multifactorial control of capillary fluid filtration and Starling’s equilibrium.28 However, preserved autoregulation during the 5-mg amlodipine dosing probably prevented additional interstitial edema accumulation in the dependent limb because limb weight showed further gains when postural vasomotion was impaired by a higher dose of the drug. This plausible conclusion, supported by a consistent body of evidence (see above), is somewhat tentative because the intraindividual correlation between gain in leg weight and attenuation of postural vasoconstrictor responses was not statistically significant. However, a correlation would not establish cause-effect relations nor could it exclude the influence of third unknown variables. Therefore additional mechanistic studies are needed to delineate more exactly the role of postural vasomotion and dependent edema during CCBs.

In agreement with previous observations obtained with drugs belonging to similar pharmacological classes,11 enalapril restrained fluid extravasation by amlodipine in that weight increments during combined treatment at 10 mg UID were similar to those induced by CCB monotherapy at one half that dosage. This clinically favorable property compounds the additive antihypertensive effect of association therapy with CCBs and ACEIs, documented again and again since the first descriptions.29 Besides inhibiting angiotensin II production, ACEIs may increase bradykinin levels, enhance the release of prostaglandins, and depress {alpha}-adrenergic responsiveness.30 None of those biological systems, however, appear to maintain or assist the postural increase in skin precapillary resistance associated with lowering one extremity below heart level, because enalapril did not alter the postural reflex control of skin vascular resistance nor did it interfere with the antagonistic effect of amlodipine. As a consequence, the attenuation of dependent fluid extravasation by the ACEI probably occurred by different biological mechanisms. Perhaps a complex interplay might take place at the microcirculatory level between more effective inhibition of precapillary resistance vessels by the CCB31 and preferential venodilatation by the ACEI,32 with a resulting limitation of the rise in capillary pressure. We have, however, no data in favor of or against this possibility.

In conclusion, amlodipine, a dihydropyridine CCB, increased intravascular fluid filtration to the extravascular compartment through mechanisms independent of interference with postural reflex skin vasoconstriction; however, effective skin blood flow autoregulation may have limited excessive fluid filtration. Pretreatment with enalapril, an ACEI, attenuated dependent fluid extravasation by amlodipine without modifying its antagonism for postural vasoconstriction.


*    Acknowledgments
 
The contribution of Ettore Pelosi, MD, and Irene Mori, MD, is gratefully acknowledged. The authors wish to thank the area managers of Merck, Sharp & Dohme (Dr Leonardo Di Bugno) and Pfizer (Dr Mario Bianchi) for the kind gifts of drugs.

Received August 3, 1999; first decision August 24, 1999; accepted September 27, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Henriksen O. Local sympathetic reflex mechanism in regulation of blood flow in human subcutaneous adipose tissue. Acta Physiol Scand. 1977;(suppl 450):1–48.
  2. Hassan AA, Tooke JE. Mechanism of the postural vasoconstrictor response in the human foot. Clin Sci (Colch). 1988;75:379–387.[Medline] [Order article via Infotrieve]
  3. Mellander S, Oberg B, Odelram H. Vascular adjustments to increased transmural pressure in cat and man with special reference to shifts in capillary fluid transfer. Acta Physiol Scand. 1964;61:34–48.[Medline] [Order article via Infotrieve]
  4. Henriksen O, Paaske WP. Local regulation of blood flow in peripheral tissue. Acta Chir Scand Suppl. 1980;502:63–74.[Medline] [Order article via Infotrieve]
  5. Rayman G, Hassan A, Tooke JE. Blood flow in the skin of the foot related to posture in diabetes mellitus. BMJ. 1986;292:87–90.
  6. Rayman G, Williams SA, Gamble J, Tooke JE. A study of factors governing fluid filtration in the diabetic foot. Eur J Clin Invest. 1994;24:830–836.[Medline] [Order article via Infotrieve]
  7. Iabichella ML, Dell’Omo G, Melillo E, Pedrinelli R. Calcium channel blockers blunt postural cutaneous vasoconstriction in hypertensive patients. Hypertension. 1997;29:931–937.
  8. van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RA, Huysmans FT. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention? J Hypertens.. 1996;14:1041–1045.[Medline] [Order article via Infotrieve]
  9. Opie LH. Calcium channel antagonists, IV: side effects and contraindications, interactions and combinations. Cardiovasc Drugs Ther. 1988;2:177–189.[Medline] [Order article via Infotrieve]
  10. Opie LH. Profiles of calcium antagonists in cardiovascular disease with special reference to second-generation agents and amlodipine. Postgrad Med J. 1991;67(suppl 5):S2–S8.
  11. Guazzi MD, De Cesare N, Galli C, Salvioni A, Tramontana C, Tamborini G, Bartorelli A. Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Circulation. 1984;70:279–284.[Abstract/Free Full Text]
  12. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension: Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol. 1997;79:431–435.[Medline] [Order article via Infotrieve]
  13. Davies RO, Gomez HJ, Irvin JD, Walker JF. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol. 1984;18(suppl 2):215S–229S.
  14. Nilsson GE, Tenland T, Oberg PA. Evaluation of a laser Doppler flowmeter for measurement of tissue blood flow. IEEE Trans Biomed Eng. 1980;27:597–604.[Medline] [Order article via Infotrieve]
  15. Low C, Neumann PJ, Dyck RD, Fealey R, Tuck RR. Evaluation of skin vasomotor reflexes by using laser Doppler velocimetry. Mayo Clinic Proc. 1983;58:583–592.[Medline] [Order article via Infotrieve]
  16. Tooke JE, Ostergren J, Fagrell B. Synchronous assessment of human skin microcirculation by laser Doppler flowmetry and dynamic capillaroscopy. Int J Microcirc Clin Exp. 1983;2:277–284.[Medline] [Order article via Infotrieve]
  17. Grant RT, Bland EF. Observations on arteriovenous anastomoses in human skin and the bird’s foot with special reference to the reaction to cold. Heart. 1931;15:385–407.
  18. Hassan AAK, Rayman G, Tooke JE. Effect of indirect heating on the postural control of skin blood flow in the human foot. Clin Sci. 1986;70:577–582.[Medline] [Order article via Infotrieve]
  19. Mahy IR, Tooke JE, Shore AC. Capillary pressure during and after incremental venous pressure elevation in man. J Physiol. 1995;485:213–219.[Medline] [Order article via Infotrieve]
  20. Henriksen O, Sejrsen P, Paaske WP, Eickhoff JH. Effect of chronic sympathetic denervation upon the transcapillary filtration rate induced by venous stasis. Acta Physiol Scand. 1983;117:171–176.[Medline] [Order article via Infotrieve]
  21. Henriksen O, Nielsen SL, Paaske WP, Sejrsen P. Autoregulation of blood flow in human cutaneous tissue. Acta Physiol Scand. 1973;89:538–543.[Medline] [Order article via Infotrieve]
  22. Noddeland H, Aukland K, Nicolaysen G. Plasma colloid osmotic pressure in venous blood from the human foot in orthostasis. Acta Physiol Scand. 1981;113:447–454.[Medline] [Order article via Infotrieve]
  23. Williams SA, Rayman G, Tooke JE. Dependent oedema and attenuation of postural vasoconstriction associated with nifedipine therapy for hypertension in diabetic patients. Eur J Clin Pharmacol. 1989;37:333–335.[Medline] [Order article via Infotrieve]
  24. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Ann Rev Pharmacol Toxicol. 1977;17:149–166.[Medline] [Order article via Infotrieve]
  25. Gustaffson D, Grande PO, Borgstrom P, Lindberg L. Effect of calcium antagonists on myogenic tone and neurogenic control of resistance and capacitance vessels in cat skeletal muscle. J Cardiovasc Pharmacol. 1988;12:213–222.
  26. Subramanian VB. Calcium antagonists in chronic stable angina pectoris. Amsterdam: Excerpta Medica. 1983;97–116:152–156, 217–229.
  27. Nilsson P, Lindholm LH, Hedner T. The Diltiazem Different Doses Study: a dose-response study of once-daily diltiazem therapy for hypertension. J Cardiovasc Pharmacol. 1996;27:469–475.[Medline] [Order article via Infotrieve]
  28. Renkin EM. Some consequences of capillary permeability to macromolecules: Starling’s hypothesis reconsidered. Am J Physiol. 1986;250:H706–H710.
  29. Stornello M, Di Rao G, Iachello M, Pisani R, Scapellato L, Pedrinelli R, Salvetti A. Hemodynamic and humoral interactions between captopril and nifedipine. Hypertension. 1983;5(pt 2):154–156.
  30. Ondetti MA. Angiotensin converting enzyme inhibitors. an overview. Hypertension. 1991;18(suppl III):III-134-III-135.
  31. Gustafsson D, Lanne T, Bjerkhoel P, Joansson P, Lundvall J. Microvascular effects and oedema formation of felodipine in man. J Hypertens. 1989;7:S161–S167.
  32. Abrams WB, Davies RO, Ferguson RK. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy. Fed Proc. 1984;43:1314–1321.[Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
HypertensionHome page
J. Jordan, S. Engeli, S. W. Boye, S. Le Breton, and D. L. Keefe
Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension
Hypertension, May 1, 2007; 49(5): 1047 - 1055.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. R. Weir, K. C. Ferdinand, J. M. Flack, K. A. Jamerson, W. Daley, S. Zelenkofske, and for the AADVANCE Investigators
A Noninferiority Comparison of Valsartan/Hydrochlorothiazide Combination Versus Amlodipine in Black Hypertensives
Hypertension, September 1, 2005; 46(3): 508 - 513.
[Abstract] [Full Text] [PDF]


Home page
J Am Board Fam MedHome page
R. P. Blankfield
Fluid Matters in Choosing Antihypertensive Therapy: A Hypothesis That the Data Speak Volumes
J Am Board Fam Med, March 1, 2005; 18(2): 113 - 124.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedrinelli, R.
Right arrow Articles by Mariani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedrinelli, R.
Right arrow Articles by Mariani, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMLODIPINE BESYLATE
*ENALAPRIL MALEATE
Medline Plus Health Information
*Edema
*High Blood Pressure
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Other hypertension